$3.62
7.10% today
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US02155H1014
Symbol
ALT

Altimmune, Inc. Stock price

$3.38
-0.76 18.36% 1M
-2.91 46.26% 6M
-3.83 53.12% YTD
-2.84 45.66% 1Y
-10.39 75.45% 3Y
-19.72 85.37% 5Y
-12.62 78.88% 10Y
-66.52 95.16% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
-0.07 2.03%
ISIN
US02155H1014
Symbol
ALT
Industry

Key metrics

Basic
Market capitalization
$274.1m
Enterprise Value
$124.3m
Net debt
positive
Cash
$149.8m
Shares outstanding
77.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
13,707.1 | 37,593.6
EV/Sales
6,215.6 | 17,047.0
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
88.7%
Return on Equity
-77.0%
ROCE
-66.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$20.0k | $7.3k
EBITDA
$-98.0m | $-109.3m
EBIT
$-98.2m | $-112.1m
Net Income
$-90.2m | $-103.6m
Free Cash Flow
$-80.3m
Growth (TTM | estimate)
Revenue
-95.1% | -63.5%
EBITDA
2.3% | -6.2%
EBIT
2.7% | -8.7%
Net Income
2.7% | -9.0%
Free Cash Flow
-10.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-490,165.0% | -1,498,798.5%
EBIT
-490,965.0%
Net
-451,200.0% | -1,420,300.5%
Free Cash Flow
-401,655.0%
More
EPS
$-1.2
FCF per Share
$-1.0
Short interest
34.9%
Employees
59
Rev per Employee
$0.0
Show more

Is Altimmune, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Altimmune, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Altimmune, Inc. forecast:

11x Buy
79%
2x Hold
14%
1x Sell
7%

Analyst Opinions

14 Analysts have issued a Altimmune, Inc. forecast:

Buy
79%
Hold
14%
Sell
7%

Financial data from Altimmune, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
0.02 0.02
95% 95%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
14% 14%
108,250%
- Research and Development Expense 77 77
9% 9%
382,850%
-98 -98
2% 2%
-490,150%
- Depreciation and Amortization 0.16 0.16
72% 72%
800%
EBIT (Operating Income) EBIT -98 -98
3% 3%
-490,965%
Net Profit -90 -90
3% 3%
-451,200%

In millions USD.

Don't miss a Thing! We will send you all news about Altimmune, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Altimmune, Inc. Stock News

Neutral
GlobeNewsWire
about 5 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
about 11 hours ago
Positive data from the IMPACT Phase 2b trial reinforces the potential for pemvidutide to be a highly differentiated MASH therapy Pemvidutide is the first product candidate to achieve statistically significant MASH resolution and weight loss at 24 weeks New data from the IMPACT trial demonstrates potentially class-leading improvements in corrected T1 (cT1), an important marker of liver inflammat...
Neutral
PRNewsWire
one day ago
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
More Altimmune, Inc. News

Company Profile

Altimmune, Inc. is a clinical stage immunotherapeutic biotechnology company. It focuses on the discovery and development of products to stimulate robust and durable immune responses for the prevention and treatment of diseases. The company's portfolio includes RespirVec and Densigen that targets to stimulate the elements of the human immune system to treat respiratory diseases, chronic infections, and cancer. Altimmune was founded in 1997 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Vipin Garg
Employees 59
Founded 1997
Website altimmune.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today